Establishment of a Pilot Medically Supervised Injection Facility in Massachusetts
Therese C. Fitzgerald (2017)
At the Massachusetts Medical Society’s Annual Meeting in 2016, the Society’s policymaking body, the House of Delegates (HOD), adopted as amended Resolution A-16 A-104, Establishment of a Pilot Medically-Supervised-Injection Facility in Massachusetts. The Society’s Board of Trustees (BOT) referred item 1 of the Resolution to the Task Force on Opioid Therapy and Physician Communication (Task Force), in consultation with the Committee on Public Health, Committee on Ethics, Grievances, and Professional Standards, the Committee on Professional Liability, and the MMS Office of the General Counsel, and item 2 to the MMS Presidential Officers:
1. That the MMS perform an internal evidence-based study of the ethical, legal, and liability considerations and feasibility of a medically-supervised injection facility (MSIF) in Massachusetts.
2. That at the conclusion of an internal study of medically-supervised injection facilities (MSIF), the Board of Trustees will report back to the House of Delegates, no later than A-17, with recommendations for an MMS advocacy position on MSIF.
1. That the MMS perform an internal evidence-based study of the ethical, legal, and liability considerations and feasibility of a medically-supervised injection facility (MSIF) in Massachusetts.
2. That at the conclusion of an internal study of medically-supervised injection facilities (MSIF), the Board of Trustees will report back to the House of Delegates, no later than A-17, with recommendations for an MMS advocacy position on MSIF.
Establishment of a Pilot Medically Supervised Injection Facility in Massachusetts
Establishment of a Pilot Medically Supervised Injection Facility in Massachusetts
Website
English
783